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Potassium and Heart Failure
Howard S. Rosman, MD,* Mihai Gheorghiade, MD,* and Sidney Goldstein, MD*

hronic heart failure is as old as the human species. Successful interventions were made over two centuries ago
with the promulgation by Withering of the Shropshire Lady's
use of foxglove in dropsy (1). One century ago. Ringer was the
first to link changes in the concentration of the blood salts (potassium, calcium, and sodium) with alterations in numerous
heart muscle functions including rhythmicity and irritability
(2,3). In 1930 Sampson and Anderson reported successful abolition of atrial and ventricular ectopic beats and tachycardia in
humans with doses of oral and intravenous potassium salts
(4). More recently, the role of electrolyte disturbances in arrhythmias and sudden death has been a subject of intense scmtiny (5-7).
This paper explores the intenelationship of potassium abnormalities and heart failure regarding their association with and
contributions to ventricular anhythmias and sudden death. We
will also discuss the electrophysiological basis by which potassium alterations cause anhythmia; the role of magnesium; the
direction of future studies; and the clinical recommendations for
electrolyte monitoring in heart failure patients.

C

Hyperkalemia and hypermagnesemia
Elevated serum potassium levels resulting from oral potassium supplementation are not uncommon. Lawson etal reported
that 3% of nearly 4,000 hospitalized patients with heart failure
were hyperkalemic, whereas 5% of the patients were hypokalemic (14). Hollenberg and Bannon recendy reported that hyperkalemia occurred in only 0.2% of 45,000 hypertensive
patients treated with maxide, a new diuretic which combines
thiazide with the potassium-sparing triamterene (15). 'Virtually
all cases of hyperkalemia in heart failure patients are caused by
potassium supplementation or potassium-sparing diuretics in
combination with baseline renal insufficiency, diabetes, or other
"potassium elevating" drugs such as angiotensin-converting
enzyme inhibitors or nonsteroidal anti-inflammatory agents
(14,15). A patient with stable semm potassium values rarely will
become hyperkalemic abruptly as a result of worsening ventricular function with further depression of cardiac output (16).
Both hypokalemia and hyperkalemia are seen in heart failure
patients. Hypokalemia is mainly a physiologic response to congestive heart failure made worse by potassium-losing diuretics;
hyperkalemia is almost always iatrogenic.

Electrolyte Abnormalities and Heart Failure
Hypokalemia and hypomagnesemia
In 1930 Harrison and colleagues demonstrated that heart
failure patients had diminished body content of potassium (8).
In subsequent years researchers unraveled the mechanism of
potassium depletion. The reduction in cardiac output and increased peripheral resistance that commonly accompany
heart failure lead to reduced renal plasma flow and stimulation
ofthe renin-angiotensin system. Due to aldosterone and nonaldosterone mechanisms, sodium is avidly held by the kidneys
at the expense of other cations, potassium and magnesium. As a
result, patients with heart failure have marked deficits of potassium and magnesium. These deficits may not be apparent in
semm measurements (9).
Plasma norepinephrine levels are increased in heart failure
patients (10), This increase in norepinephrine appears to be proportional to the degree of symptoms rather than the severity of
heart failure (11), Catecholamines, via a specific Pj-adrenoceptor effect, cause a further lowering of semm potassium (12). The
link between catecholamines and hypokalemia is thus more intriguing since we know that plasma norepinephrine levels are
important predictors of mortality in heart failure patients (13).
Diuretics and digitalis have been the mainstays of heart
failure treatment since the 1950s. Diuretics directly cause increased renal excretion of potassium and magnesium and also
induce hyperaldosteronism and metabolic alkalosis.
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Electrolyte Abnormalities and
Ventricular Arrhythmias
Sampson elegantly reviewed the series of discoveries in animals and man which linked depletion of potassium to ventricular
anhythmias, and repletion of potassium to anhythmia abolition
and. although rarely, to anhythmia aggravation (2,17,18). More
recendy, the significance of diuretic-induced hypokalemia in
hypertensive patients has been debated at great length and with
much zeal (19-23).
Hypertensive patients
Diuretics have been the foundation of antihypertensive therapy. The benefit of these drugs in reducing mortality from
stroke, renal failure, and chronic heart failure is generally accepted (23). Wbether the diuretic-induced potassium loss causes
anhythmias, which pose a separate risk to the patient, has been
body contested (24-27). The most comprehensive, cunent hypothesis is that hypertensive patients with evidence of organic
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heart disease are at great risk of diuretic-associated ventricular
ectopy, while hypertensive patients without evidence of heart
disease are not atrisk(28).
Acute myocardial infarction patients
Nordrehaug and colleagues have provided data which clearly
show that hypokalemia is a risk factor for ventricular arrhythmias (29) and ventricular fibrillation (30) in the setting of
acute myocardial infarction. In a prospective study of 60 patients with acute myocardial infarction, serum potassium as a
continuous variable was inversely related to the incidence of unifocal ventricular ectopy and ventricular tachycardia. This relationship remained significant even after elimination of digitalis
and left ventricular dysfunction by multivariate analysis (29).
In an earlier study of 1,074 patients with acute myocardial infarction, Nordrehaug and von der Lippe found that 17% of
hypokalemic patients (potassium < 3,5 mmol/L) subsequentiy
developed ventricular fibrillation compared to only 7% of normokalemic patients (30).
Heart failure patients with and without digitalis
It is well accepted that hypokalemia is associated with ventricular anhythmias in digitalized patients (23,31,32). Padents
with chronic heart failure historically have been treated with
digitalis, but since digitalis is a highly toxic inotrope it is no
longer prescribed routinely. Recent studies show that complex
ventricular anhythmias are present in heart failure patients even
in the absence of digitalis (33-35). This led Packer et al to describe congestive heart failure as the "most anhythmogenic disorder in cardiovascular medicine" (36). The importance of
hypokalemia in ventricular anhythmias in heart failure patients
off digitalis has not yet been proven.

Electrolyte Abnormalities and Sudden Death
Scant information is available on the electrolyte status of humans just before sudden death. Surprisingly, not much data exist
concerning serum electrolytes subsequent to sudden death.
Thompson and Cobb examined electrolytes, blood gas values,
and diuretic histories of 115 patients immediately after resuscitation from out-of-hospital ventricular fibrillation (37). They
found semm potassium levels less than 3.6 mmol/L in 49% of
these patients and hypokalemia in 19% of patients with acute
myocardial infarction and 9% of ambulatory patients with coronary heart disease. Because no strong relationship between diuretic usage and hypokalemia was found, they concluded that
hypokalemia may have occuned not preceding resuscitation but
as a result of it. They speculated that bicarbonate therapy could
have shifted potassium intracellularly without causing extracellular alkalosis.
Goldstein et al recently reported on 227 survivors of out-ofhospital cardiac anest (38). Further analysis of the data revealed
that 68% ofthe patients were hypokalemic (potassium < 3.6
mmol/L) within six hours of resuscitation. An additional 43 survivors of cardiac anest showed no evidence of coronary artery
disease. Among these survivors were 14 patients with dilated
cardiomyopathy (Table). In this small subset, 11 patients (78%)
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were found to be hypokalemic postresuscitation. Furthermore,
hypokalemia was present in seven of eight patients on diuretics
(mean 3.2 mmol/L) and in four of six patients not on diuretics
(mean 3.6 mmol/L).
Since Thompson and Cobb's publication (37), the work of
Brown et al (12) has indicated that catecholamines cause a significant decrease in semm potassium. The anest itself leads to
endogenous release of catechols, and epinephrine is frequendy
administered during resuscitation.
Hypokalemia is thus frequently present subsequent to cardiac
anest and resuscitation. It is tempting to speculate that it may be
the mechanism of the anest, but no data cunentiy exist to confirm this hypothesis.

Importance of Electrolyte Abnormalities
in Chronic Heart Failure
Sudden death occurs in nearly 40% of heart failure patients
(6). Its incidence is equal to death secondary to progressive ventricular dysfunction. Sudden death is most commonly caused by
ventricular tachycardia or fibrillation. Left ventricular dysfunction and ventricular anhythmias act synergistically to determine
subsequent mortality (6,39).
The aforementioned data strongly suggest that hypokalemia
is associated with chronic heart failure and with anhythmic sudden death in heart failure. The cunent question is whether it is
important in causing sudden death.

Electrophysiology
A sound, theoretical basis exists for potassium to be an important contributor to ventricular arrhythmia (40). "Ventricular
tachyanhythmias most often result from reentrant rhythm disturbances. Hypokalemia prolongs action-potential duration far
more than it extends the refractory period. This imbalance establishes the milieu for unidirectional block and reentrant arrhythmias. This propensity for anhythmia is heightened by the
increased automaticity and decreased conductivity of ventriculartissuerendered hypokalemic.

Table
Postresuscitation Data in Dilated Cardiomyopathy Patients
Patient
1
2
3
4
5
6
7
g
9
10
11
12
13
14

pH
Serum Potassium*
(mmol/L)
(if present)
2.8
3.0
3.1
3.2
3.2
3.;
3.3
3.4
3.5
3.5
3.5
3.6
4,0
4.5

Digoxin

Diuretic

ycs
yes
ycs
ye:-.
ycs
no
no
no
ye.s
yes
yes
no
no
no

yes
yes
ycs
yes
ycs
no
no
no
ycs
yes
no
yes
no
no

7.30

7.35
7.30
7.40
7.40
7.25
7.50

^Lowest recorded value in first six hours postresuscitation.

Potassium and Heart Failure—Rosman et al

175

Clinical data
Hypokalemia can cause ventricular anhythmia and death in
heart failure patients on digitalis, Cohn et al speculated that the
increase in plasma norepinephrine found in heart failure patients
could be a cause of mortality (13), It is equally tenable that diuretics and increased norepinephrine may be the link between
hypokalemia and death.

Hypothesis
No conclusive evidence exists regarding hypokalemia as an
important independent contributor toward sudden death in patients with chronic heart failure. This conclusion would require
a randomized, prospective study with a control group of hypokalemic heart failure padents not replenished with potassium.
This study will never be perfonned. Therefore, clinicians must
continue to weigh evidence and create hypotheses and treatment
plans with available but incomplete information.
Until contrary information is available, it should be assumed
that hypokalemia is an independent cause of death in heart
failure patients whether hypokalemia is a result of diuretics or of
the body's compensatory response to decreased cardiac output
with activation ofthe sympathetic nervous system and reninangiotensin system.

Therapeutic Recommendations
All heart failure patients, not only those receiving digitalis
preparations, should receive careful treatment when potassium
levels fall below 3.5 mmol/L. Potassium repletion can be attained by potassium supplementation, potassium-sparing
diuretics, and also by therapy with ACE inhibitors or beta
blockers.
Vasodilators play an increasingly important role in the treatment of congestive heart failure patients. It was first suggested at
a recent prospective trial that vasodilators prolong life in congestive heart failure patients (41). Angiotensin-converting
enzyme inhibitors are potent vasodilators which serve to block
aldosterone and reduce renal losses of potassium and magnesium. A randomized, blinded study showed that captopril reduced the incidence of ventricular ectopic beats and episodes of
ventricular tachycardia in heart failure patients (42).
Beta blockers raise serum potassium and magnesium by
blocking ^j-receptor stimulation by catecholamines (12). These
agents rarely alleviate symptoms in tachycardic congestive heart
failure patients. Some investigators have reported improved
mortality when sympatholytic drugs were used in congestive
heart failure padents (43,44).
Theoretically, potassium-sparing diuretics may be preferable
to potassium supplementation because they are better tolerated
by patients and maintain body stores of magnesium.
As mentioned eariier, hypokalemia is often present simply as
a physiologic response to congestive heart failure. However, hyperkalemia is generally iatrogenic and life-threatening. It is essential that all patients at risk of hyperkalemia be carefully
monitored. Contraindications to the use of potassium-repledng
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medications, such as renal insufficiency and diabetes mellitus,
and various other drugs, including the nonsteroidal and antiinflammatory agents, must not be overlooked.
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